세계의 광선각화증 치료 시장 보고서(2025년)
Actinic Keratosis Treatment Global Market Report 2025
상품코드 : 1821611
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,666,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,635,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,605,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

광선각화증 치료 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.7%로 45억 9,000만 달러로 성장할 전망입니다. 예측기간의 성장은 환자 교육과 참여, 디지털 건강 통합, 인지도 향상, 예방 피부과에 대한 주력, 맞춤형 의료 동향에 기인할 것으로 예상됩니다. 예측기간의 주요 동향은 병용요법으로의 이동, 기술 진보, 개인화 치료 접근법, 이환율 증가, 저침습 치료 등입니다.

향후 5년간의 예측 성장률 7.7%는 이 시장의 과거 예측에서 0.3% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 영국과 폴란드에서 생산되는 냉동요법 장비 및 플루오로우라실 외용 크림에 대한 미국의 접근을 제한하고 치료비를 증가시켜 임상 효율을 저하시킬 수 있습니다. 또한 상호관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

광선각화증의 유병률 증가는 광선각화증 치료 시장의 성장 궤도를 견인할 것으로 예측됩니다. 광선각화증은 장시간의 일광 노출의 결과로서, 거친 비늘 모양의 피부 반점으로 나타나 전암병변을 완화하기 위한 치료가 필요합니다. 광선각화증 환자의 급증은 치료 옵션에 대한 수요 증가를 강조하고, 의약품 연구를 추진하며, 국소 치료의 사용을 제안합니다. 세계 암 연구기금 인터내셔널의 2022년 2월 보고서에 따르면, 광선각화증의 발생률은 2020년 신규 증례 15만건 이상에서 2022년에는 19만7,700건으로 급증하였으며 이는 이 증상에 대처하기 위한 치료 진보의 매우 중요한 역할을 강조하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Actinic keratoses treatment addresses the skin condition resulting from sun exposure, primarily manifesting on the face, scalp, backs of the hands, or chest. This treatment aims to mitigate the risk of developing the condition by safeguarding the skin from ultraviolet (UV) rays and minimizing regular sun exposure.

The primary categories of actinic keratosis treatment include topical applications, procedural interventions, photodynamic therapy, and other modalities. Topical treatment involves the application of specific medications like fluorouracil cream, imiquimod cream, ingenol mebutate gel, and diclofenac gel. These medications are utilized across various healthcare settings, including hospitals, private dermatology clinics, laser therapy centers, cancer treatment facilities, spas, rejuvenation centers, and in homecare practices.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The actinic keratosis treatment market research report is one of a series of new reports from The Business Research Company that provides actinic keratosis treatment market statistics, including actinic keratosis treatment industry global market size, regional shares, competitors with an actinic keratosis treatment market share, detailed actinic keratosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis treatment industry. This actinic keratosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actinic keratosis treatment market size has grown strongly in recent years. It will grow from $3.2 billion in 2024 to $3.41 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to treatment adherence, market competition, patient education initiatives, dermatological practices, research and clinical trials.

The actinic keratosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.59 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to patient education and engagement, digital health integration, growing awareness, focus on preventive dermatology, personalized medicine trends. Major trends in the forecast period include shift towards combination therapies, technological advancements, personalized treatment approaches, increasing incidence rates, minimally invasive treatments.

The forecast of 7.7% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. access to cryotherapy devices and topical fluorouracil creams produced in the UK and Poland, raising treatment expenses and reducing clinical efficiency. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating prevalence of actinic keratosis is anticipated to drive the growth trajectory of the market for actinic keratosis treatment. Actinic keratosis, a consequence of prolonged sun exposure, manifests as rough, scaly skin patches and necessitates treatment to mitigate precancerous lesions. The surge in actinic keratosis cases underscores the amplified demand for treatment options, driving pharmaceutical research and advocating the use of topical treatments. According to the World Cancer Research Fund International's February 2022 report, the incidence of actinic keratosis surged from over 150,000 new cases in 2020 to 197,700 cases in 2022, emphasizing the pivotal role of treatment advancements in addressing this condition.

The expanding demographic of elderly individuals is poised to be a significant catalyst propelling the growth trajectory of the actinic keratosis treatment market. Addressing the needs of the geriatric populace-typically aged 65 and older-remains pivotal due to their susceptibility to actinic keratosis, attributed to prolonged sun exposure and skin aging. Actinic keratosis treatment interventions are crucial in curbing precancerous skin lesions, consequently reducing the risk of skin cancer among this demographic. As per the World Health Organization's projection in October 2022, the population aged 60 and above is estimated to surge from 1 billion in 2020 to 1.4 billion by 2030, with a subsequent doubling to 2.1 billion by 2050. This demographic shift underscores the necessity for focused treatments catering to the geriatric population susceptible to actinic keratosis.

Major companies in the actinic keratosis treatment market are concentrating on developing innovative products, such as prescription medications, to enhance treatment efficacy, improve patient outcomes, and broaden their product offerings. Prescription medications are drugs that can only be dispensed with a healthcare provider's written authorization, specifying the medication name, dosage, and duration. These drugs are intended for treating specific medical conditions and necessitate careful monitoring due to potential side effects. For example, in December 2022, Biofrontera AG, a Germany-based pharmaceutical company, introduced Ameluz, a topical gel containing 5-aminolevulinic acid. This gel is used in conjunction with photodynamic therapy (PDT) to treat mild to moderate actinic keratoses (AK) and certain types of basal cell carcinoma. The treatment involves applying the gel to the affected skin areas, followed by exposure to light from a BF-RhodoLED lamp, which activates the medication.

Leading companies in the actinic keratosis treatment market are prioritizing advancements in technologies like positioning sensors to boost treatment accuracy, enhance patient outcomes, and optimize therapy delivery by precisely targeting light or topical agents to the affected skin areas. Positioning sensor technology refers to systems that accurately identify the location of an object or surface, often utilized to guide and improve treatment in medical procedures. For example, in December 2022, Biofrontera Inc., a US-based biopharmaceutical firm, introduced the RhodoLED XL Lamp. This lamp is approved for use in conjunction with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, to treat mild-to-moderate actinic keratosis on the face and scalp. This approval highlights the lamp's role in enhancing the efficacy of photodynamic therapy (PDT).

In March 2022, Coegin Pharma, a Sweden-based company at the forefront of a phase I/II trial featuring their lead candidate AVX001 targeting actinic keratosis and actively engaged in the preclinical development of AVX420 for conditions like leukemia and chronic kidney disease, executed a merger with Follicum. This strategic alliance aimed to reinforce Coegin Pharma's drug development portfolio by placing a significant emphasis on tackling diabetes complications. Follicum, a biotech company based in Sweden, brings complementary expertise and resources to Coegin Pharma, fortifying its position in drug development and enhancing its focus on addressing various medical conditions.

Major companies operating in the actinic keratosis treatment market are Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline PLC, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals PLC, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company PLC, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.

North America was the largest region in the actinic keratosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the actinic keratosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The actinic keratoses treatment market includes revenues earned by entities by providing cryotherapy, laser therapy, chemical peels, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Actinic Keratosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on actinic keratosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for actinic keratosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The actinic keratosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Actinic Keratosis Treatment Market Characteristics

3. Actinic Keratosis Treatment Market Trends And Strategies

4. Actinic Keratosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Actinic Keratosis Treatment Growth Analysis And Strategic Analysis Framework

6. Actinic Keratosis Treatment Market Segmentation

7. Actinic Keratosis Treatment Market Regional And Country Analysis

8. Asia-Pacific Actinic Keratosis Treatment Market

9. China Actinic Keratosis Treatment Market

10. India Actinic Keratosis Treatment Market

11. Japan Actinic Keratosis Treatment Market

12. Australia Actinic Keratosis Treatment Market

13. Indonesia Actinic Keratosis Treatment Market

14. South Korea Actinic Keratosis Treatment Market

15. Western Europe Actinic Keratosis Treatment Market

16. UK Actinic Keratosis Treatment Market

17. Germany Actinic Keratosis Treatment Market

18. France Actinic Keratosis Treatment Market

19. Italy Actinic Keratosis Treatment Market

20. Spain Actinic Keratosis Treatment Market

21. Eastern Europe Actinic Keratosis Treatment Market

22. Russia Actinic Keratosis Treatment Market

23. North America Actinic Keratosis Treatment Market

24. USA Actinic Keratosis Treatment Market

25. Canada Actinic Keratosis Treatment Market

26. South America Actinic Keratosis Treatment Market

27. Brazil Actinic Keratosis Treatment Market

28. Middle East Actinic Keratosis Treatment Market

29. Africa Actinic Keratosis Treatment Market

30. Actinic Keratosis Treatment Market Competitive Landscape And Company Profiles

31. Actinic Keratosis Treatment Market Other Major And Innovative Companies

32. Global Actinic Keratosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Actinic Keratosis Treatment Market

34. Recent Developments In The Actinic Keratosis Treatment Market

35. Actinic Keratosis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기